Boston Common Asset Management LLC Takes $2.74 Million Position in argenex SE $ARGX

Boston Common Asset Management LLC acquired a new stake in argenex SE (NASDAQ:ARGX) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 3,753 shares of the company’s stock, valued at approximately $2,741,000.

A number of other hedge funds also recently added to or reduced their stakes in the business. Assenagon Asset Management S.A. bought a new stake in shares of argenex in the 4th quarter valued at about $20,475,000. Sivik Global Healthcare LLC purchased a new stake in shares of argenex in the 4th quarter worth approximately $1,261,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of argenex by 22.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,846 shares of the company’s stock valued at $9,121,000 after purchasing an additional 2,018 shares in the last quarter. SG Americas Securities LLC boosted its stake in shares of argenex by 94.9% during the fourth quarter. SG Americas Securities LLC now owns 3,179 shares of the company’s stock valued at $2,673,000 after purchasing an additional 1,548 shares in the last quarter. Finally, M&T Bank Corp increased its holdings in argenex by 34.8% during the fourth quarter. M&T Bank Corp now owns 4,980 shares of the company’s stock valued at $4,188,000 after buying an additional 1,286 shares during the period. 60.32% of the stock is owned by hedge funds and other institutional investors.

argenex Price Performance

NASDAQ ARGX opened at $860.55 on Monday. The firm has a market cap of $53.84 billion, a PE ratio of 38.31, a price-to-earnings-growth ratio of 1.06 and a beta of 0.45. The company has a 50 day moving average price of $860.97 and a 200 day moving average price of $813.43. argenex SE has a 52 week low of $560.91 and a 52 week high of $953.58.

argenex (NASDAQ:ARGX) last announced its earnings results on Tuesday, March 31st. The company reported $5.52 earnings per share for the quarter. argenex had a net margin of 31.31% and a return on equity of 44.37%. The company had revenue of $1.31 billion during the quarter. On average, equities research analysts anticipate that argenex SE will post 26.27 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. HC Wainwright reissued a “buy” rating and issued a $940.00 price objective on shares of argenex in a research note on Thursday, June 25th. Wedbush reaffirmed an “outperform” rating and set a $1,000.00 target price on shares of argenex in a research report on Thursday, June 11th. Oppenheimer cut their price target on argenex from $1,060.00 to $1,014.00 and set an “outperform” rating on the stock in a report on Thursday, April 2nd. Wells Fargo & Company boosted their price target on argenex from $1,260.00 to $1,291.00 and gave the stock an “overweight” rating in a research report on Monday, June 1st. Finally, Royal Bank Of Canada upped their price objective on argenex from $890.00 to $945.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 7th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, argenex presently has an average rating of “Moderate Buy” and an average target price of $1,037.61.

argenex Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.